The life sciences sector operates by a different set of rules than traditional commercial real estate. While general-use office buildings can accommodate a range of industries with modest modifications, life sciences facilities are highly specialized, requiring unique utilities, storage, structural specifications, and tailored layouts based on the tenant’s scientific focus, from wet and dry labs to clean rooms and biomanufacturing.
This complexity becomes most evident as companies transition from early-stage research and development (R&D) to commercialization, especially biomanufacturing. For emerging firms, the move from lab to production is not just a real estate decision — it’s a defining operational inflection point and increasingly where many encounter friction and delays.
A Market in Transition and Well Positioned for Tenants
After a decade-long demand boom beginning in the early 2010s, the life sciences real estate market entered a more challenging phase. Development pipelines were disrupted by the pandemic, tighter capital, reduced funding, and a slowdown in IPO activity.
The result is elevated vacancy, reaching as high as 40 percent to 50 percent in some submarkets, including Northern California’s life sciences node centered on South San Francisco, and a clear shift toward a tenant-favorable environment. For early-stage biomanufacturing companies, this presents a rare window of opportunity. Landlords are more aggressive, competition is increasing, and occupiers are leveraging conditions to renegotiate their leases or relocate.
At the same time, consolidation through mergers, closures, and acquisitions continues to reshape the landscape, triggering rapid expansion or vacancy shifts and increasing the importance of proactive real estate strategy.
The move from lab to production is where many companies encounter friction and delays.
Where the Process Breaks Down
Despite favorable conditions, many early-stage companies struggle in the transition from R&D to commercialization to production. Friction typically arises in the programming and funding stage, well before a lease is signed, or during plan execution.
The most common issue is inadequate upfront programming. In a company’s speed to market, executives often underestimate the time, cost, and complexity required to define operational needs. For a 10,000- to 50,000-square-foot biomanufacturing facility, this phase alone can take one to two years. Without that clarity, site selection becomes reactive rather than proactive.
Permitting is another bottleneck. Many properties lack the appropriate entitlement approvals for scaled life sciences work, especially biomanufacturing. Retrofitting entitlements onto existing facilities to loosen production caps, operating times, material handling, ingress and egress, and conditional-use permits requiring public hearings can delay projects significantly. In some cases, companies secure space before completing sufficient diligence, only to find regulations restrict future expansion.
50%
Infrastructure constraints also play a growing role, particularly power availability. In some markets, limited electrical capacity can delay occupancy by up to two years if upgrades are required, posing serious risks for companies operating on tight funding and production timelines.
How to Avoid Missteps
A recurring theme among early-stage firms is the tendency to deprioritize real estate strategy and accept convenient, though more costly, solutions. Engaging specialized resources early in the planning stage can properly align real estate with a company’s growth trajectory. This requires the early onboarding of subject matter experts with experience in government relations, design and construction, site selection, resource availability, economic concessions, and more.
Without upfront programming, site selection becomes reactive rather than strategic.
Another frequent misstep is overreliance on incubator space. While the best incubators offer space flexibility, ready access to shared infrastructure, and strong management, companies often stay longer than prudent because it is perceived as easier than relocating. Consequently, this approach can constrain growth, create challenges associated with sharing space with co-tenants, and, most importantly, drive a steep increase in unit costs compared to a standalone facility.
Scaling into dedicated space requires calculated risk and ongoing sensitivity analysis across both quantitative and qualitative factors. Companies that succeed plan far ahead, commit to a defined program, and secure space aligned with long-term objectives, not just immediate needs.
A Shifting Geographic Landscape
Location strategy is also evolving. Traditional hubs like Boston and the San Francisco Bay Area remain dominant, but as these mature markets grapple with land constraints, high costs, taxes, strict environmental regulations, and other limitations, biomanufacturing is pushing further into emerging markets.
Companies often stay in incubator space longer than they should—and pay for it.
Secondary locations, including Texas and North Carolina, are gaining traction because of lower costs, available land, government subsidies, and strong academic ecosystems. The Texas Medical Center-anchored life sciences cluster in Houston has emerged as a national contender, while areas such as Vacaville, Fremont, and Pleasanton near South San Francisco have attracted larger-scale biomanufacturing operations.
That said, location decisions remain highly dependent on programmatic needs, including access to specialized labor, proximity to research clusters, aligned government support, vendors, industry cohorts, and academic centers.
Aligning Real Estate With the Business
Ultimately, the transition from R&D to commercialization to production represents a series of strategic milestones requiring alignment between land, labor, resources, capital, and growth potential. Companies that navigate the process successfully treat real estate as a core component of their business strategy, investing early to define requirements, understand constraints, and structure for flexibility and scale.
Resources available to emerging life sciences companies include LabSpaceDirectory.com, Biscred’s Life Sciences Guide, and regional organizations like BioNJ and Life Sciences Pennsylvania.
In today’s market, the opportunity is there, but realizing it requires discipline, foresight, and informed decision-making before urgency dictates the process.
